Green Cross to develop high-volume vaccine for elders for first time in Korea

Published: 2017-10-23 16:03:49

Updated: 2017-10-23 16:03:49

An influenza vaccine which is more effective for elders will be developed.

Green Cross(CEO Eun-Cheol Huh) announced on the 19^th that it acquired approval for the Phase I clinical trial plan of a high-volume tetravalent influenza vaccine ‘GC3114’ from the Ministry of Food and Drug Safety.

This is the first time for a Korean pharmaceutical company to develop a flu vaccine which contains a highe...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.